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ABSTRACT
Given that stress and major depression are putative causal factors in alcohol
consumption, the exploration of the genes and the associated neurobiological
mechanisms that influence the relationship between stress, depression, and alcohol
dependence (AD) is a first step toward the development of novel medications for AD.
The tachykinin receptor 1 (TACR1) gene is a promising candidate gene, showing an
association with stress-related behaviors (Thorsell et al., 2010), major depression
(Kramer et al., 2004), and AD treatment outcome (George et al., 2008). The purpose of
the current study was to determine if TACR1 single nucleotide polymorphisms (SNPs)
are associated with (1) blood oxygen level dependent (BOLD) activation in response to
alcohol cues, (2)DSM-IV-TR AD symptom count,(3) DSM-IV-TR depression diagnoses,
and (4) DSM-IV-TR AD symptom count in a large, publicly available dataset. To address
these questions, the current study examined relationships between neural responses
during a craving task in 326 individuals with alcohol use disorders and SNPs within the
TACR1 gene. Of the 70 SNPs tested, rs3771863 was predictive of AD symptom count
and BOLD activation in response to alcohol cues, regardless of major depression
status, as well as AD symptom count in the SAGE dataset. Additionally, rs3771810 and
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rs12477553 also predicted BOLD activation in response to alcohol cues, but the
relationship between these SNPs and AD symptom count was moderated by major
depression status. Finally, rs1106855 is a SNP associated with BOLD activation that
should be explored for possible functional significance due to its location within a stop
codon. The exploration of TACR1 receptor antagonism as a form of AD treatment
should be further examined in less heterogeneous samples, as it might be most
effective for those with primary or secondary alcohol dependence in addition to a
diagnosis of major depression.
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Introduction
Current pharmacological and psychosocial treatments for alcohol dependence
(AD) are only modestly effective; naltrexone, 12 step facilitation, motivational
enhancement approaches, and cognitive behavioral therapies have led to 12 month
abstinence rates between 17 to 35% (Miller et al., 2001). These results speak to the
large variability of biological and psychosocial mechanisms involved in AD. Many of the
most important mechanisms in the development of AD are heritable susceptibility
factors, which contribute 50-60% of the disease risk (Dick et al., 2006). These genetic
factors interact with environmental factors to produce and maintain the disease state,
although studies to date have only explained 2-3% of the genetic variance in diagnosis
(Dick et al., 2006; Goldman et al., 2006).
Nonetheless, researchers are now exploring the idea of personalized medicine;
that is, patients with AD could potentially be matched to various treatments based on
genetic profiles that have been linked to the functional neurobiological mechanisms
which maintain AD. The tachykinin receptor 1 (TACR1) gene has shown an association
with an affective neuroimaging phenotype (Gilman and Hommer, 2010) as well as AD
treatment outcome (George et al., 2008). Because the TACR1 receptor is also
mechanistically related to negative affect and depression (Heilig et al., 2007; Kramer et
al., 2004), which are putative causal factors of AD, the TACR1 gene should be
considered as a potential point of pharmacological intervention for AD.
Candidate gene associations.
To date, many genetic studies of AD have been based on candidate gene
approaches. That is, single genes were chosen based on theoretical connections to AD.
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When the function of a gene is known, candidate gene studies can facilitate the
development of mechanistic hypotheses. Such studies have identified variations in
several chromosomal regions, including regions of chromosomes 1,2,4,7, and 11, which
are related to intermediate phenotypes associated with AD (Dick et al., 2006). Genes
that have been implicated in AD involve synaptic plasticity, growth regulation, cation
transport, lipid signaling, gene regulation and cell adhesion (Treutlein et al., 2009).
While some genes have been replicated in multiple studies, replication at the
level of single nucleotide polymorphisms (SNPs) is difficult because one must control for
the number of statistical tests performed, as a single gene can contain thousands of
SNPs. Furthermore, many findings linking genes to diagnostic phenotypes have not
been replicated, despite large sample sizes, because the effects of single genes on
neurological activity are much like that of tributaries of a river which come together to
influence downstream effects, (i.e., neurotransmission, long term potentiation, etc; see
Cannon & Keller, 2006). The development of brain based intermediate phenotypes
could allow for discovery of gene-neurobiology associations, in addition to genephenotype associations.
The BOLD response is a powerful intermediate phenotype for candidate gene studies
The current study used Blood Oxygen Level Dependent (BOLD) response to
alcohol cues as an intermediate phenotype to explore an association between a novel
candidate gene and AD. Functional neuroimaging enables an evaluation of the
association between changes at the molecular level (due to genetic variation) and
changes in in vivo brain function, as measured by the BOLD response. In AD research,
the primary advantage of neuroimaging is that it is an objective indicator of the AD
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phenotype, as compared to subjective indicators, such as self-report measures and
clinician diagnoses.
Alcohol interacts with many different areas of the brain, especially those
associated with reward. Once a person is addicted, craving for alcohol is related to
ventral striatal activation (Heinz et al., 2009; Kalivas & Volkow, 2005). The ventral
tegmental area also facilitates drug intake (Volkow et al., 2006). Alcohol associated
cues are processed in the anterior cingulate, hippocampus, amygdala and medial
prefrontal cortex (Kalivas & O‟Brien, 2007; Heinz et al., 2009). The insula is an area
associated with both conscious and visceral aspects of craving (Brody et al., 2002) and
the maintenance of addiction (Koob & Volkow, 2009; Naqvi et al., 2007). The rewarding
effects of alcohol have also been linked to dopamine release in the nucleus accumbens
(Heinz et al., 2009; Kalivas, Volkow, &Seamans, 2005). Thus, one would expect to see
BOLD activation to alcohol cues in these areas.
Studies have shown that these brain areas are also associated with risk factors
and behavioral indices of AD. For example, fMRI studies have shown that alcohol,
marijuana, and polydrug cues elicit activation in the right insula, left anterior caudate
and left prefrontal cortex in college students at risk for alcohol dependence (Bates et al.,
2010). Additionally, increased activity in the right insula in response to drug cues
predicts relapse to methamphetamine use (Paulus et al., 2007). Furthermore, people
with substance use disorders have been shown to have abnormal processing of reward
predictions. For example, prediction errors in those with AD correlate with phasic
dopamine release in the ventral striatum. Park and colleagues (2010) therefore suggest

3

that the connectivity of the frontostriatal regions during the performance of prediction
errors is different between those with and without AD.
Several studies have associated brain-based phenotypes (BOLD activation) for
alcohol dependence with specific candidate genes (e.g., CNR1, OPRM1, DRD4; Filbey
et al., 2008; Hutchison et al., 2008). For example, GABRA2 genotypes correlate with
larger activation in the medial prefrontal cortex to alcohol odors as opposed to appetitive
controls- an effect that is moderated by family history of alcoholism (Karaken et al.,
2010). Additionally, the low expressing allele of the 5HTT promoter is associated with
heightened amygdala response to emotional cues, a risk factor for alcohol dependence
(Rao et al., 2007).
Moreover, recent studies have linked candidate genes to treatment outcomes.
For example, individuals with a single base pair substitution in the OPRM1 gene
respond to a naltrexone regimen better than those carrying the more common allele
(Anton et al., 2008); that is, those with the rare alleles have fewer drinking days and
drink less during drinking episodes. In addition, studies with other medications (e.g.,
topiramate, olanzapine) have found that genetic variables predict treatment outcomes
(e.g., Hutchison et al., 2006; Hutchison, 2008; Seniveratne et al., 2009).
TACR1 is a promising candidate gene associated with AD.
Recently, Seneviratne and colleagues (2009) linked one SNP of the TACR1 gene
(rs6715729) and two haplotypes (formed by combinations of rs6715729-rs735668rs6741029) to susceptibility for AD in Caucasians (odds ratio for first haplotype 1.89
(95% CI= 1.16, 3.11) and 11.31(95% CI= 3.62, 32.35 for the second haplotype). The
TACR1 gene encodes neurokinin 1 (NK1) receptors. The gene resides on the 2p11
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region of chromosome 2 and is approximately 115kB in length and contains 5 exons. It
is transcribed into 4 variants (two found in the human brain) via alternative promoter
usage, differential slicing or both (Seneviratne et al., 2009). A peptide known as
substance P (SP) is the endogenous ligand that binds to the TACR1 receptor, a G
protein coupled receptor found in both the central and peripheral nervous systems. SP
is an 11-amino acid peptide belonging to the neurokinin family, whose other members
include substance K (neurokinin 2) and neuromedin K (neurokinin 3). In the human
brain, TACR1 receptors are the predominantly expressed subtype of neurokinin
receptors (Rigby et al., 2005).
Seniveratne and colleagues (2009) postulated that the SNPs that were
significantly associated with AD could affect SP signal transduction by altering receptor
density through alternative splicing of TACR1 messenger ribonucleic acid (mRNA).
Preclinical Studies of TACR1 and alcohol.
In preclinical studies performed by George and colleagues (2008), mice
genetically deficient in TACR1 receptors showed a marked decrease in voluntary
alcohol consumption and an increased sensitivity to the sedative effects of alcohol
relative to wild type mice. This effect can be mimicked in wild type mice by
administering a TACR1 antagonist (Thorsell et al., 2010). These mice have altered
reward systems, which are normalized by the administration of a TACR1 receptor
antagonist (Yan et al., 2009). Intracerebral infusion of Substance P into the amygdala
also reduces alcohol consumption in both wild type rats and “anxious” rats (June et al.,
2009). Furthermore, the effect of TACR1 genotypes on alcohol consumption has been
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shown to be via a direct regulation of alcohol consumption, rather than a developmental
effect on NK1 function or structure (Thorsell et al., 2010).
TACR1 association with BOLD activation.
Gilman and Hommer (2008) showed that fMRI responses to affective stimuli also
suggested beneficial effects of the TACR1 receptor antagonist. Placebo-treated
alcoholics showed robust responses to negative affective images, while alcoholics who
received LY 686017 (a TACR1 antagonist) demonstrated less activation in the insula
and medial temporal gyrus in response to negative images. Additionally, alcoholics who
received the TACR1 receptor antagonist showed greater activation to positive
International Affective Picture System (IAPS) images, suggesting a shift in the
emotional valence of positive and negative stimuli. This is an important finding because
greater activation to positive stimuli is predictive of lower alcohol consumption in the first
six months after detoxification (Heinz et al., 2007).
TACR1 potential for AD treatment.
George and colleagues (2008) demonstrated the clinical efficacy of a TACR1
antagonist for AD. In a randomized controlled experimental study, they treated recently
detoxified alcoholic in-patients with a TACR1 receptor antagonist, LY 686017, (n = 25)
or placebo (n = 25). The TACR1 receptor antagonist suppressed spontaneous alcohol
cravings, improved overall well-being, blunted cravings induced by the Trier social
stress test, and attenuated concomitant cortisol responses.
Because George and colleagues (2008) demonstrated that TACR1 antagonists
represent a promising treatment for AD, it is important to determine whether
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polymorphisms in the gene for the TACR1 receptor may be associated with differential
treatment response.
TACR1 is associated with stress, an important factor in the development and
maintenance of AD.
Studies of TACR1 receptor antagonists suggest a major role of the SP-TACR1
receptor system in stress-related behaviors (Sommer et al., 2008). The expression of
SP and TACR1 receptors has been mapped to neural circuits involving the caudate,
putamen, amygdala, striatum, hippocampus and other components of stress-response
circuitry (Duffy, 2004; Hietala et al., 2005). Within these areas, the concentration of SP
increases in response to noxious or aversive stimulation. More directly, both in
experimental animals and humans, exposure to stressors has been shown to facilitate a
release of SP in the amygdala, while selective blockade of TACR1 receptors inhibits the
associated behavioral stress responses (Duric &McCarson, 2005; Ebner et al., 2004;
Furmark et al., 2005; Kramer et al., 2004; Michelgard et al., 2007).
TACR1 activation by SP interacts with other neurotransmitters such as 5HT,
GABA, DA, Glu, ACh, and NE (Ebner, Rupniak, Saria, & Singewald, 2004; Levesque et
al., 2007), which have been implicated in addictive processes. Substance P modulates
the release of GABA in the substania nigra and interacts with the mu opioid receptor
(OPRM1) in modulating nocioceptive transmission (Pinto et al., 2008). Norepinephrine
release in the hippocampus increases TACR1 receptor activity, which in turn inhibits
serotonin reuptake in the brain (Gobbi & Blier, 2005; Gobbi et al., 2007; Haddjeri & Blier
2008).

7

TACR1 is associated with negative affect and depression, additional factors involved in
the development and maintenance AD.
Preclinical studies support NK1 antagonism as an antidepressant.
Both pharmacological blockade and genetic deletion of TACR1 receptors
decrease emotionality and depression-related behaviors in animal models (Frisch et al.,
2010). When depression is operationalized physiologically, TACR1 antagonism reduces
separation-induced vocalizations in guinea pigs and lowers glucocorticoid secretion by
rats during the forced swim test and mice during tail suspension paradigms (Mclean,
2005). Furthermore, in a tree shrew model of depression, increases in hippocampal
neurogenesis and volume, comparable to those due to SSRI administration, can be
obtained by administering a TACR1 antagonist (Czeh et al., 2001). This finding has
been replicated in TACR1 knockout mice: they respond to TACR1 antagonism the way
wild type mice respond to antidepressants (van der Hart et al., 2002).
Clinical studies show mixed results regarding TACR1 antagonism for depression.
While three studies have shown efficacy of TACR1 antagonists in treating
depression at the same level as fluoxetine and better than placebo (Herpfer and Lied,
2005; Kramer et al., 2004; Ranga and Krishnan, 2002), others have found it does not
perform better than placebo (Rupniak et al., 1999). It has been suggested that a
subpopulation of severely depressed patients respond to NK1 antagonism because they
have higher initial levels of Substance P than nonresponders (Bondy et al., 2003; Murtra
et al., 2000). Higher levels of SP correspond with high stress reactivity, a risk factor for
depression (Ebner et al., 2009; Frisch et al., 2010).

8

In sum, the TACR1 receptor is mechanistically related to stress, depression, and
addiction. The connection between TACR1, stress, and depression is important
because stress, negative affect, and depression influence the course of AD.
Stress contributes to the development and maintenance of AD.
Drinking to cope with stress has been qualitatively distinguished from drinking for
positive reinforcement, but the role of stress in the development of alcohol dependence
is not clear. It is known that negative affect is predictive of adolescent substance use
(Ohannessian & Hesselbrock, 2008). Additionally, drinking to cope motives mediate the
relationship between generalized anxiety and heavy drinking in college students
(Goldsmith et al., 2009). Preclinical and clinical studies also show a connection between
anxiety and propensities to self-administer alcohol (Ciccocioppo et al., 2006).
More extensive information is available on the role of stress in relapse. There is a
general consensus among researchers that stress does play a role in relapse, but the
exact mechanisms remain unknown (Heilig et al., 2010). Elevated stress reactivity in
early withdrawal from alcohol and cocaine predicts increased craving and shorter time
to relapse (Sinha, 2008; Sinha et al., 2009). Furthermore, stress and negative affect are
often cited by AD patients as significant causes for relapse to alcoholic drinking many
months after treatment (McKay et al., 1995).
This stress response in AD patients is largely due to changes in cellular
metabolism in the extended amygdala (including the bed nucleus of the stria terminals
and the nucleus accumbens) due to alcohol consumption the extended amygdala is
responsible for the emotional component of pain processing (Koob &Volkow, 2010). In
AD individuals, a specific stress related dysregulation is maintained by alcoholic
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drinking; this dysregulation develops via neuroadaptations in stress pathways and
reward circuits in the brain over the course of repeated cycles of abstinence and relapse
(Heilig & Koob, 2007; Holgter et al., 2000; Koob et al., 2004; Sinha, 2007). Negative
affect and withdrawal therefore begin to function as conditioned stimuli capable of
eliciting craving (Stewart et al., 1984). Post acute withdrawal, which can last more than
a year, is associated with negative affect, attenuated pleasure from natural rewards,
dysphoria, malaise, irritability, etc. (George et al., 2008; Gilman and Hommer, 2008;
Heilig et al., 2010; Heinz et al., 2007; Koob, 2009). As a result of post-acute withdrawal
symptoms, craving and drug seeking behavior is reinstated in order to achieve short
term homeostasis.
Each time alcohol is used in response to stress or drug cues, the connection
between that cue and affective relief is further solidified through long-term potentiation
in the striatum (De Filippo et al., 2009). The ventral striatum connects motivational
aspects of salient environmental and interoceptive stimuli with motor reactions (Wrase
et al., 2007). Goldstein and colleagues (2009) have hypothesized that the switch form
voluntary drug use to habitual use might be related to changes in the neural
representation of craving moving from prefrontal regions to the striatum. This change
could lead to compromised insight into behavior and an unconscious drive to drink. As
described earlier, the TACR1 receptor is highly expressed in the ventral striatum and
throughout the extended amygdala; hence it may play a role in developing and
maintaining alcoholic drinking in response to stress.
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A bidirectional relationship also exists between MD and AD.
A review of 35 articles discussing the rates of alcohol abuse among depressed
patients showed that 16% of depressed patients had current alcohol problems, as
opposed to 7% of the general population (Sullivan et al., 2005). Of inpatients receiving
treatment for alcohol dependence, 25% meet DSM-IV-TR criteria for depression.
Furthermore, higher depression rates exist among binge drinkers than among nonheavy drinkers (16%, 11% respectively; Levola et al., 2011; Manninen et al., 2006).
Three theoretical etiologies for comorbid AD and depression exist: (1) depressed people
self medicate with alcohol, (2) alcohol induces depressive symptoms, and (3) shared
biological and environmental risk factors cause both disorders (Kendler et al., 1993).
Most studies support the self-medication hypothesis, with alcohol dependence
developing secondarily to a depression diagnosis, especially for those high in neurosis
or loneliness and among single people (Boschloo et al., 2011).
Study aims and hypotheses
In summary, stress and major depression are putative causal factors in the
development of and relapses to alcohol dependence. Understanding how genetic
variations and the associated neurobiological mechanisms influence the relationship
between stress and/or depression and alcohol is an important step toward developing
treatments for AD. The current research combined the study of a candidate gene
(TACR1) and a neurobiological phenotype for AD. It was hypothesized that significant
clusters within the incentive regions of the brain, such as the insula, striatum, and
amygdala, and the control regions of the brain, such as the prefrontal cortex, would be
associated with genotypic variation in the TACR1 gene. It was also hypothesized that
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the same SNPs that are significantly associated with BOLD response would also be
significantly associated with AD symptom count both in our sample and in an
independent sample: the Study of Addictions: Genetics and Environment Genome Wide
Association study (SAGE GWAS). Additionally, the relationship between SNPs and
symptom count was hypothesized to be mediated by brain activation in the incentive
regions of the brain and moderated by lifetime and current major depression.
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Methods
Participants
Sample characteristics. Three hundred twenty-six heavy drinking individuals (100
females, 30.9%) were recruited from a large metropolitan area in the southwest region
of the United States. The sample consisted of a racially diverse group, with 48.1%
identifying themselves as White, 27.8% Latino, 4.7%, Native American, 0.6% Asian,
0.6% Native Hawaiian/Pacific Islander, 1.9% Black, and 16.3% Mixed. The average age
of participants was 31.86 (SD = 9.72). The average number of drinks per drinking day in
the last month was 7.35 (SD = 4.16) and the mean Alcohol Dependence Score was
13.47 (SD = 8.17).
Recruitment and Screening. Participants were recruited from the greater
Albuquerque area by newspaper advertisements, personal contact, internet
advertisements, and Mind Research Network sponsored outreach programs. Research
participation was open to treatment seeking individuals as well as individuals who were
not interested in changing their alcohol use. To be considered for participation in the
treatment study, participants had to meet several criteria. Treatment seeking individuals
had to (a) have a primary diagnosis of alcohol dependence, (b) have been within 21
days of their last drink, (c) obtained a score less than 8 on the Clinical Institute
Withdrawal Assessment for Alcohol Scale (CIWA; Sullivan, Sykora, Schneiderman,
Naranjo, & Sellers, 1989), and (d) met specific criteria for alcohol use (females drink
>14/week, males drink >21/week). Non-treatment seeking participants were eligible for
the study if they had 5 binge drinking episodes (4 or more drinks for females, 5 or more
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for males) per month for the past 3 months and had no history of treatment for alcohol
problems.
Procedures
Study Protocol. All participants received informed consent. Drinking alcohol
within 24 hours of the fMRI session was expressly prohibited. Each subject was
breathalyzed at the start of the session to ensure that they had not been drinking; only
participants with a breath alcohol concentration of zero were allowed to participate in
the fMRI session. Participants underwent the Structured Clinical Interview for DSM-IV
and filled out pencil and paper measures related to personality, drinking history, drinking
problems, and family history of alcohol problems prior to scanning.
fMRI Acquisition. All MRI data was collected on a 3T Siemens Trio (Erlangen,
Germany) whole body scanner. Prior to the acquisition of anatomical scans, localizer
scans were acquired. An echo-planar gradient-echo pulse sequence (TR=2000ms,
TE=29, flip angle=75°) was acquired with an 8-channel head coil, and images were
acquired parallel to the ventral surface of a participant‟s orbitofrontal cortex to reduce
signal dropout and distortion in this region. Each volume acquired consisted of 33 axial
slices (64x64 matrix, 3.75 x 3.75 mm2, 3.5 mm thickness, 1 mm gap).
We utilized a taste cue task previously reported to elicit BOLD response in
mesocorticolimbic areas (medial prefrontal cortex, amygdala, striatum, caudate) where
TACR1 is highly expressed (Filbey et al., 2007, 2008). All taste stimuli were delivered to
the participants via Teflon tubing using a computer controlled delivery system as
described by Frank and colleagues (2003). The alcohol stimuli used were each
subject‟s preferred alcoholic beverage, whereas the control stimulus was kept constant
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across subjects. The control stimulus (litchi juice) provided an appetitive control for the
activation of the mesocorticolimbic circuitry (Berns et al., 2001). During the EPI run,
there were 12 pseudorandomized alcohol and control trials (six of each). Each trial
consisted of a 24-s taste delivery period, followed by a washout period to allow the
liquid taste to dissipate before the next trial. The word „TASTE‟ was visually presented
throughout the taste period. The washout period consisted of a 16-s rest period during
which the word „REST‟ appeared on the screen; nothing was delivered during the rest
period. The washout was followed by a 2-s urge question and a 2-s prompt screen
During the urge question, the subjects were asked to rate their current subjective urge
to drink alcohol using a scale of 1 (no urge at all) to 4 (very high urge).
Image analysis. The first 7 volumes of each functional run were discarded to
allow the magnet to reach steady state. MCFLIRT (FMRIB) was used to motion correct
images within a run; each image within the run was aligned to the first volume within the
run. Images were then deskulled using BET, spatially smoothed with a 8 mm full-width
half-max Gaussian kernel, temporally filtered using a high-pass filter of 100 sec, and
grand mean intensity normalized; all of these steps were performed using FEAT
(FMRIB Expert Analysis Tool).Statistical analyses were performed using the general
linear model as implemented in FEAT. Customized square waveforms representing the
condition of interest (taste, urge, control, rest) and the duration of stimulus presentation
were convolved with a double gamma hemodynamic response function. In addition,
movement parameters estimated by MCFLIRT were used as covariates within the
multiple regressions.
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Time series analyses were conducted using FILM (FMRIB Improved Linear
Model) with local autocorrelation estimation. Contrast maps were created by
contrasting alcohol taste vs. control taste conditions, i.e. activation in response to
alcohol with activation in response to the control stimulus subtracted. Contrast maps
were then registered to the participant‟s high-resolution anatomical image and the MNI
152 brain template using FLIRT (FMRIB Linear Image Registration Tool). Individual
runs were combined within participants using a fixed effects model, which determines
estimates of each participant‟s contrast map as well as variance map. These second
level analyses were then used in a third level analysis using FLAME (FMRIB Local
Analysis of Mixed Effects) stage 1 only. Before computing group level statistics, all
second level images were registered to the MNI template. When examining group level
maps at the whole brain level, we used minimum cluster sizes of 64 2x2x2 mm3 voxels
thresholded at z=2.32, p<.005.
Collection of Genetic Material. Participants were instructed to generate and
deliver 5 ml of saliva in to a sterile 50 ml conical centrifuge tube. The saliva sample was
then placed in the refrigerator and lysis buffer was added within 24 hours. Tris-HCl, pH
8; EDTA, pH 8; SDS and NaCl were added at 100 mM, 20 mM, 0.5% and 125 mM final
concentrations; respectively. The tubes were refrigerated until the DNA is extracted,
usually within 48 hours. Proteinase K (0.2 mg/ml) was added and the tubes were
incubated at 65°C for 60 minutes. An equal volume of isopropyl alcohol was then added
to each tube, the contents were mixed, and the DNA was collected by centrifugation at
3,500 x g for 10 minutes. The DNA pellet was rinsed once with one ml of 50% isopropyl
alcohol and allowed to air dry. For RNase treatment, 20 ug/ml RNAse A and 50 U/ml
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RNase T1 were added and incubated at 37oC for 30 minutes. To precipitate the DNA,
two volumes of 95% ethanol was added and mixed by gentle inversion then collected by
centrifugation at 3,500 xg for 15 minutes. The samples were allowed to air dry followed
by re-suspension in 1 ml of 10 mM Tris-HCl, 10 mM EDTA buffer, pH 8.0, and placed in
a 1.8 ml cryovial. The concentration of DNA was calculated from the absorbance at 260
nm analysis and then adjusted to a concentration of 10 ng/μL.
The DNA was then purified and quantified in preparation for fragmentation and
ethanol precipitation. The DNA was re-suspended in hybridization buffer and applied to
the bead chip array for an overnight incubation. The amplified and fragmented DNA
samples annealed to locus-specific 50-mers (covalently linked to one of over 1,000,000
bead types) during the hybridization step. Following hybridization, the arrays were
washed to eliminate unhybridized and non-specifically hybridized DNA. One bead type
corresponds to each allele per SNP locus. The samples then underwent single base
extension and staining followed by more washing. The arrays were allowed to dry and
then scanned using the Illumina iScan system and in turn analyzed using Illumina‟s
software for automated genotype calling.
Analysis of the scanned results was achieved using Illumina‟s BeadStudio
software in conjunction with the BeadStudio genotyping module. BeadStudio Software
is a modular analysis tool for genotyping, gene expression, and methylation
applications. The data was then filtered in BeadStudio for call rate, and minor allele
frequency to remove bad samples and bad SNPs. BeadStudio comes equipped with
several plug-ins to generate compatible files for further analysis using third party and/or
custom software packages.
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Data Analysis
The goals of the current research were (1) to examine the association between
TACR1 genotypes and BOLD activation in response to alcohol cues, (2) to determine if
any significant associations between SNPs and AD symptom count were mediated by
BOLD activation or moderated by depression and (3) to test whether these associations
replicated in an independent clinical sample. It was hypothesized that significant
clusters within the incentive regions of the brain, such as the insula, striatum, and
amygdala, would be associated with genotypic variation in the TACR1 gene. It was also
hypothesized that the same SNPs that are significantly associated with our brain based
phenotype would also be significantly associated with AD symptom count our sample
and in an independent GWAS sample (SAGE). Lastly, it was hypothesized that the
relationships between SNPs and AD symptom count were mediated by brain activity
and/or moderated by major depression.
Hypothesis 1: TACR1 genotype association with BOLD response
We included known SNPs 20,000 base pairs up and downstream from the
TACR1 gene in this analysis in order to capture any potentially important SNPs in the 3‟
or 5‟ untranslated region (UTR). 808 SNPs were identified via the UCSC Genome
Browser, 108 of which were represented on the Illumnia 1MDuo Chip used in this
analysis. The analyses were focused on the 70 of the 108 SNPs that met the following
criteria: 1) each allele represented in at least 20% of the population in the Southwestern
United States 2) each allele represented in at least 20 people of our sample and 3) the
SNP was used in the SAGE GWAS. Each SNP was analyzed separately using an
additive model (AA > Ab> bb) in FSL. For the analysis, we had two broadly defined
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regions of interest, or masks, which encapsulate the incentive areas (ventral tegmental
area, ventral and dorsal striatum, medial prefrontal cortex, putamen, caudate, insula,
and orbitofrontal cortex) and control areas (prefrontal cortex and precentral gyri) of the
brain. We had two intermediate phenotypes for the alcohol>control contrast: (1) BOLD
response within the incentive mask and (2) BOLD response within the control mask.
The association test for each SNP was a regression of the SNP on a measure the
spatial extent of significant BOLD response in each mask and the associated p value.
The first step was to examine the association between the group variable (in this
case a SNP) and the alcohol > control difference in BOLD activation at each voxel
within the masks. Each voxel within the mask was tested for an association with each
SNP and only those voxels that exceed a statistical threshold (z > 2.32) were
highlighted in a spatial map of the active voxels within the mask. Cluster size was
defined as the largest number of spatially contiguous voxels which exceed the statistical
threshold within the mask. To control for the number of voxels tested in the first step,
the analysis software evaluated cluster size in relation to the number of voxels tested
(e.g., 8732 in our incentive mask) and calculated a probability distribution for how likely
it would be to find a contiguous cluster of a specific size by chance (5% of the time for p
< .05), given the number of voxels tested. A cluster that exceeded this corrected cluster
threshold indicated that the SNP was significantly associated with the cluster at p < .05.
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Hypotheses 2: Relationship between TACR1 SNPs and AD symptom count.
SNPs that were both previously identified as associated with psychiatric conditions and
significantly associated with brain activation in response to alcohol cues were tested for
a significant correlation with both current and/or lifetime AD symptom count.
Hypothesis 3: Mediation of relationship between TACR1 SNPs and AD symptom count
by BOLD activation.
If a significant relationship between the SNP and AD symptom count was
identified, it was tested to see if the association was mediated by BOLD activation using
general linear modeling. BOLD activation was quantified as mean percent signal
change in the incentive or control masks. AD lifetime and current symptom count was
determined via the Structured Clinical Interview for the DSM-IV-TR. First, analyses were
run to see if BOLD activation predicted AD symptom count. If both the SNP and BOLD
signal independently predicted AD symptom count, they were both used as predictors of
AD symptom count in a regression analysis. If the significant relationship between a
SNP and AD symptom count became insignificant when BOLD was also used as a
predictor, this was considered evidence of mediation.
Hypothesis 4: Moderation of relationship between TACR1 SNPs and AD symptom count
by major depression.
The same significant relationships between SNPs and AD symptom count were
also tested for a moderating effect of either a lifetime or current diagnosis of major
depression, according to DSM-IV-TR, criteria using general linear modeling. Diagnosis
of depression was determined via the Structured Clinical Interview for the DSM-IV-TR.
Moderation was evident if regression of AD symptom count on the SNP in the
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unaffected group was significantly different from regression of AD symptom count on
the SNP in the depressed group.
Hypothesis 5: Replication of TACR1 association with a clinical phenotype.
The health research sample of the SAGE dataset was downloaded from dbGap
to test the association between TACR1 SNPs and a clinical phenotype. We included
only non-related Caucasian individuals (n=2605), as the rest of the sample was mostly
African American and only 3% Hispanic. 69 TACR1 SNPs were assayed in this GWAS.
In the SAGE sample, genotypes were coded log-additively (0, 1, 2 copies of the minor
allele). Covariates represented sex, age, and two principal components indexing
continuous variation in race/ethnicity. Correlation analyses between genotype for each
SNP and number of AD symptoms was performed.
Power Analysis and Multiple Comparisons Correction
With a family-wise alpha level of 0.05, a sample size of n=326, and three
genotype groups, we could detect an effect size of f=0.17 with .80 power. Additionally,
we previously corrected for multiple comparisons per voxel in the fMRI analysis by
applying an ROI threshold of p<0.05 to the contrast maps. The power to detect an
association between three genotype groups of TACR1 SNPs and SCID symptom count
in the SAGE dataset with a sample of n=2605 was therefore more than adequate. In
order to avoid type 1 errors, we used a conservative approach, a Bonferroni correction,
in the determination of the significance of all p-values for genetic associations between
each SNP and activation and also between each SNP and symptom count. The results
were also assessed for statistical significance using a False Discovery Rate correction.
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Results
The pattern of BOLD activity in response to the alcohol taste cue task replicated
previous findings (Claus et al., in submission), with activation in the alcohol minus litchi
contrast mainly in the mesocorticolimbic pathways where TACR1 receptors are highly
expressed. These pathways include connections among the putamen, caudate,
amygdala, cingulated, pallidum, and lateral orbitofrontal cortex. The sample included
heavy drinkers, with average AD lifetime and current symptom counts of 6 ± 3, mean
Alcohol Dependence Scale score 18 ±8, and mean Alcohol Use Disorders Identification
Test score of 19 ±8. Twenty percent of the sample had current major depression
diagnoses and one third of the sample had a lifetime diagnosis of major depression.
Hypothesis 1
BOLD activation in the incentive and control masks in response to gustatory
alcohol cues was predicted by 16 of the 70 SNPs in the TACR1 gene that met inclusion
criteria (Table 2). All of the SNPs associated with BOLD activation are located in
introns; one SNP, rs1106855, is located in a stop codon near the 3‟ region of the gene.
It should be noted, however, that if a Bonferroni correction were to be applied to this
data (p = 0.05/70 SNPs x 2 ROIs = 0.05/140=0.00036) only 3 of these SNPs would
significantly associated with BOLD activation at a level above chance. If one were to
apply a False Discovery Rate (FDR) correction for multiple tests, 7 out of the 140 tests
would be expected to be significant by chance. Using an FDR correction, we can be
confident that some of these associations are not due to chance alone.
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Hypothesis 2
SNPs previously identified in the literature that also significantly predicted BOLD
activation before a Bonferroni or FDR correction (rs3771810, rs3771863, rs12477554,
and rs1106855) were tested for an association with AD symptom count. Rs3771810
predicted current AD symptom (p=0.037, df= 325) while rs3771863 and rs12477554
predicted lifetime AD symptom count (p= 0.036 and 0.030, respectively, df=325).
Rs1106855 genotypes did not predict AD symptom count. However, these analyses did
not pass a family wise error correction.
Hypothesis 3
Because each of the SNPs previously identified in the literature predicted AD
symptom count, in addition to predicting BOLD activation in our sample, a mediational
analysis was performed. It was hypothesized that the relationship between the SNPs
and current or lifetime AD symptom count was mediated by BOLD activation. However,
brain activation in the incentive, control, or specific ROIs did not predict AD symptom
count. Therefore, there is no mediation of the association between TACR1 SNPs and
AD symptom count by BOLD activation, despite the fact that there is a significant
association of those same TACR1 SNPs and BOLD activation in response to alcohol
cues.
Hypothesis 4
Since TACR1 is associated with depression, an analysis was performed to see if
the relationship between the four SNPs previously reported in the literature (rs3771810,
rs3771863, rs1247754) and AD symptom count was moderated by lifetime or current
major depression. Rs12477554 predicted lifetime AD symptom count for those without
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any lifetime history of depression (p<0.036, df=325), but not for those with a history of
depression. Rs3771810 predicted current AD symptom count for those participants with
current major depression (p<0.033, df=325), but not for those without current major
depression. These moderating relationships are responsible for the association of AD
symptom counts with the SNPs in the full sample. The relationships between rs3771863
and rs1106855 and AD symptom count was not moderated by lifetime or current MD.
Hypothesis 5
Three of 70 TACR1 SNPs predicted AD symptom count in the SAGE sample
(rs10490308, rs11688000, and rs3771863) at a statistically significant level (p =.0054,
0.0273, 0.0335 respectively, df=69) (Table 3). The correlation between rs3371863 and
AD symptom count in this sample is of note because rs3771863 significantly predicted
brain activation in the full sample and AD symptom count in the full sample (Figure 5).
However, it should be noted that these associations do not pass an FDR correction for
the number of statistical tests performed (0.05 x 70=3.5).
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Discussion
The goal of this research was to find genetic variations in the TACR1 gene that
predicted not only the clinical phenotype of alcohol dependence, but also a
neurobiological intermediate phenotype, BOLD activation during alcohol craving. 16
TACR1 SNPs predicted activation in response to alcohol cues in brain areas related to
emotion and learning. Specifically, the SNPs were significantly related to activity in the
putamen and caudate, areas involved in learning and memory. They were also
significant associations with areas involving emotional perception and processing,
including the amygdala and cingulate, as well as areas involved in executive function
and decision making, including the insula and orbitofrontal cortex. This supports the
idea that TACR1 has a role in the formation or maintenance of the association between
stress, negative affect, and depression and alcohol use.
One SNP, rs3771863, was predictive of AD symptom count and BOLD activation
in response to alcohol cues, regardless of major depression status (Figure 2). It also
was predictive of AD symptom count in the SAGE Genome Wide Association Study.
However, it is unlikely that this SNP is a functional determinant of TACR1 receptor
structure or activity because it is within an intron in the gene. The functions of introns
remain largely unknown, although some have been implicated in RNA slicing (Mattick,
2004). Thus, it is not a good candidate as a point of potential pharmacological
intervention. It might be in high LD with a functional SNP in the 5‟ untranslated or
promoter region, which is more likely to alter TACR1 receptor number, structure, and
function (Figure 6).
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However, one SNP with potential functional significance, rs1106855, was
associated with BOLD activation in response to alcohol cues (Figure 4). This SNP is in
a intron, but is located within a stop codon. Therefore, it could affect the amount of
mRNA produced by a cell and therefore alter the number of receptors or the binding
properties of the TACR1 receptors.
For two other SNPs that predicted BOLD activation in response to alcohol cues
(rs3771810 and rs12477553) (Figures 1 and 3), major depression status moderated the
relationships with AD symptom counts. Neither SNP was associated with AD symptom
count in the SAGE sample. This finding parallels previous research regarding TACR1
antagonists as a treatment for AD for depression. That is, TACR1 antagonism has
proven most effective as a treatment for depression in those with higher Substance P
levels and correspondingly, more severe depression (Bondy et al., 2003; Murtra et al.,
2000). For these people, AD could be secondary to a primary depression diagnosis, one
of many potential etiologies for AD.
Each of the SNPs associated with AD symptom count in the imaging sample or
the SAGE sample (rs3771863, ra3771810, rs1106855, rs124477553) are in regions of
the TACR1 gene with high potential for functional significance (Figure 6). However, the
association with BOLD activation in response to alcohol cues identified many more
potential SNPs of interest. As an intermediate phenotype, it is closer to the gene‟s
neurobiological activity, and thus was able to detect smaller, but potentially important
effects of SNPs on this intermediate phenotype and the corresponding clinical
phenotype (Figure 5).
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These findings must be interpreted within the limitations of this study. First,
because only common SNP variants were used in these analyses, the potential effects
of rare SNP variants could have been missed. Deep sequencing is a new technique
which might reveal rare, but functional SNPs and should be applied to the TACR1 gene
in future studies.
Moreover, although the sample was not underpowered to find BOLD effects
during the craving task or to detect associations between SNPs intermediate phenotype
and the clinical phenotype, the number of statistical tests performed was extremely
high. Despite the fact that linkage disequilibrium among SNPs within a gene decreases
the effective number of statistical tests, the ability to detect the effect of a single SNP on
BOLD activation remains limited. All SNPs and corresponding genes interact with
thousands of other SNPs and hundreds of other genes to influence cellular activity.
Activity at the cellular level then influences tissue specific functions, especially
neurobiological function in different brain areas. The interactions among genes are not
always additive either; some genes work to decrease the activity of other genes and
their products. Therefore any statement linking a complex phenotype solely to the
function of one gene is an over-simplification. Personalized medicine based on single
gene function is therefore limited and a cellular systems approach, combining the study
many genes or many thousands of SNPs that underlie neural activity at once, might be
more fruitful alternative.
Another limitation of this study was the use of DSM-IV-TR AD symptom count as
the clinical phenotype because two people can be diagnosed with AD without sharing
even one symptom. Thus, as a phenotype, it is not uniform or very informative. This
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underscores the importance of intermediate phenotypes, such as BOLD activation, in
the parsing of AD variation to aid in the development of novel medications. Better
assessments of AD do exist, such as the Alcohol Use Disorders Identification Test
(AUDIT, Barbor et al., 1992) and the Alcohol Dependence Scale (ADS, Skinner & Allen,
1982). Unlike AD symptom count, BOLD response does predict scores on these
measures (Claus et al., in submission). However, these variables were unavailable for
the SAGE GWAS sample, so AD symptom count was used in both analyses so that a
direct comparison could be made between the two samples.
An additional limitation of this study was the lack of a stress measurement.
Because TACR1 is involved in the stress response and stress is highly associated with
both alcohol dependence and depression, measures of stress should be included in
future studies. The design could be further improved by manipulating stress prior to or
during exposure to alcohol cues. Furthermore, the disentanglement of stress, negative
affect, and depression as separate constructs, in addition to distinct operationalization
would further work in this area immensely. Perhaps they are different manifestations of
the sample physiological response or negative affect and depression are results of
external stress.
A final, but important, limitation of this study was previously described as a
strength of this study: the use of BOLD signal as an intermediate phenotype. This
approach has high statistical power to detect small effects, but it remains controversial.
The idea that brain function is intermediate between genetic and phenotypic profiles is
widely accepted and BOLD response is a representation of brain activity. However, the
BOLD response itself is based upon a series of assumptions and indirect evidence that
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it reflect neural activity. Solid evidence linking BOLD to changes in neural activity would
strengthen all results based on this intermediate phenotype. Additionally, the mean
percent BOLD signal change for each region of interest (whole brain, incentive mask,
and control mask) was used as a variable in these analyses. How this maps onto a
meaningful effect size measure is unclear. Furthermore, the use of BOLD response in
response to this particular task may not be the most appropriate endophenotype. There
is evidence that the BOLD response to the task is dependent on current levels of
drinking and age (Claus et al., in submission). Endophenotypes are, by definition,
unchanging based on the organism‟s state as they are supposed to reflect enduring
traits (Cannon & Keller 2006; Gottesman & Gould 2003).
In sum, despite these caveats, this study adds to the literature regarding the role
of TACR1 receptors in alcohol dependence and depression. SNPs with potential
functional significant were identified and areas of that TACR1 gene that are most likely
to be functional were identified. These SNPs should also be considered as potential
biomarkers, if not points of pharmacological interventions. TACR1 receptor antagonism
as a form of treatment should be examined in less heterogeneous groups, as it might be
very effective for those with primary or secondary alcohol dependence in addition to a
diagnosis of major depression.
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Participant Characteristics

Mean

SD

Range

Age

31.86

9.72

21 - 56

Estimated verbal IQ (WASI)

54.80

10.11

28 – 76

Alcohol dependence (ADS)

13.47

8.17

1 - 43

Average drinks per drinking day (past month)

7.35

4.16

.7 – 39

Proportion of drinking days

0.59

0.25

.07 - 1

Proportion of binge drinking days

0.43

0.28

0-1

Proportion of Current Cigarette Smokers

0.49

n/a

0-1

Depressive symptoms (BDI)

11.98

9.64

0 – 47

Anxiety symptoms (BAI)

9.59

8.92

1 - 40

Table 1. This ethnically diverse adult sample included heavy binge drinkers, with mild
to severe depression and anxiety symptoms. One half of the participants were current
cigarette smokers.
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Incentive Largest Cluster Size, contiguous
SNP
voxels
Control Largest Cluster Size, contgiuous voxels
rs3755459
468 (0.002)
1145 (0.000000119)
rs3821320
99 (0.186)
396 (0.0011)
rs3771863
119 (0.0137)
383 (0.00132)
rs2024512
26 (0.601)
273 (0.00738)
rs3771869
26 (0.601)
269 (0.00789)
rs6546952
159 (0.0767)
253 (0.0102)
rs3771836
90 (0.213)
229 (0.0158)
rs3771811
44 (0.447)
204 (0.0245)
rs3771846
39 (0.485)
203 (0.0252)
rs4439987
59 (0.35)
172 (0.0442)
rs12477554
33 (0.536)
171 (0.0455)
rs10168354
79 (0.254)
170 (0.0461)
rs11680998
184 (0.0548)
170 (0.0474)
rs3755468
84 (0.234)
166 (0.0498)
rs3771810
254 (0.221)
133 (0.0498)
rs6546951
562 (0.000795)
82 (0.275)
rs1106855
244 (0.222)
40 (0.51)

Whole Brain Largest Cluster Size, contigous voxels
4189 (0.00000000000227)
664 (0.0034)
3348 (0.000000000143)
506 (0.0143)
392 (0.00133)
390 (0.0446)
812 (0.000954)
341 (0.0739)
309 (0.109)
196 (0.352)
488 (0.0171)
177 (0.428)
591 (0.00676)
233 (0.237)
774 (0.00133)
390 (0.0446)
2138 (0.000000119)

Table 2. SNPs associated with BOLD activation, largest cluster sizes per mask and in the whole brain, bold & italic values
significant at p< 0.05, corrected for multiple tests.
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SNP
Position
Top Strand Corr/Trend P
Corr/Trend -log10 P
rs10490308
75335883
[A/C]
0.005371097
2.269936968
rs11688000
75146665
[A/G]
0.027260033
1.56447363
rs3771863
75273222
[A/G]
0.033508291
1.474847722

Table 3. TACR1 SNPs associated with AD symptom count in the Study of Alcohol
Genetics and Environment Genome Wide Association Study, p<0.05, uncorrected for
multiple comparisons.
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Insula and Putamen

Insula

Putamen

Figure 1. BOLD activation significantly associated with rs3771810 genotypes, corrected
map, z>2.32.
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Pallidum

Medial Prefrontal Cortex

Figure 2. BOLD activation significantly associated with rs3771863 genotypes, corrected
map, z > 2.32.
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Orbitofrontal Cortex

Amygdala

Orbitofrontal Cortex

Figure 3. BOLD activation significantly associated with rs12477554 genotypes,
uncorrected map, z > 2.32
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Insula

Insula

Putamen

Figure 4. BOLD activation associated with rs1106855 genotypes, uncorrected map,
z>2.32.
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14

12

rs3755459, whole brain p=2.27E-12
10

rs3771863, whole brain p= 1.34E-10

8

-log 10 p value

SAGE

rs1106855, whole brain p= 1.19E-7

Whole Brain

6

4

rs3771810, whole brain p=0.00133
2

0
75100000

rs124777554, whole brain p= 0.0171
rs3771863, SAGE p=0.033

rs11688000, SAGE p=0.027

rs10490308, SAGE p=0.0054

rs11688000, whole brain p= 0.927
75150000

75200000

75250000

Position in Gene

75300000

75350000

Figure 5. Significant Associations between SNPs and BOLD activation and significant associations between SNPs and
AD symptom count in the SAGE GWAS, a value above 1.5 indicates a statistical significant association.
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rs1106855

rs3771810

rs12477554

rs3771863

rs11688000

Figure 5. Linkage Disequlibrium plot of TACR1 gene. SNPs previously identified in the literature that were also
significantly associated with BOLD response to alcohol cues are indicated with red arrows. SNPs that were significantly
associated with AD symptom count in SAGE are indicated with blue arrows.
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